Early study suggests long-term antiretroviral therapy with protease inhibitors might prevent COVID-19 infection

A preliminary study to be presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal (23-26 April), suggests that people living with HIV who are on antiretroviral treatment (ART) with protease inhibitors (PI), may have a lower risk of COVID-19 infection. The study is by Dr. Steve Nguala from the Intercommunal Hospital Center of Villeneuve-Saint-Georges and the General Hospital of Melun in France and colleagues.

source https://medicalxpress.com/news/2022-03-early-long-term-antiretroviral-therapy-protease.html